- The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for novel cancer therapies.
HEIDELBERG, Germany, February 06, 2025 / Biotech Newswire / -- German independent research institute BioMed X announces the successful completion of its oncology research project in partnership with Merck. The data generated by this project has been acquired by Merck for further development, potentially leading to new therapeutic approaches in precision oncology.
Launched in August 2022, the collaboration aimed to unravel the mechanisms behind the formation, propagation, and impact of ecDNA in cancer cells using state-of-the-art single-cell screening and spatial technologies. The project was led by Dr. Alexandros Drainas, winner of the BioMed X Innovation Boot Camp, and mentored by Dr. Sebastian M. Waszak, Assistant Professor at EPFL, Lausanne, Switzerland. Industry guidance provided by Dr. Balca Mardin, Head of Target Discovery & Research at Merck.
The multidisciplinary BioMed X team made significant strides in understanding ecDNA biology by addressing fundamental questions, such as:
- How can we detect and trace ecDNA?
- How is ecDNA formed, and which genes promote or inhibit its formation?
- How are ecDNA structures formed, propagated, and maintained?
The team’s research identified genes that may reduce ecDNA abundance in cancer cells. Additionally, Team EDC developed advanced spatial technologies to explore how ecDNA localization affects cancer cell adaptability. The project was completed earlier than expected thanks to the promising and unexpected results achieved by the team. These early findings may offer promising strategies for mitigating cancer heterogeneity and reducing the mechanisms driving therapeutic resistance, potentially improving the efficacy of existing treatments.
Dr. Thomas Rückle, Senior Vice President Research at the BioMed X Institute, emphasized the importance of this achievement: “Our collaboration with Merck has once again demonstrated the power of combining academic curiosity with industrial expertise. The knowledge gained from this project not only advances cancer research but also showcases the potential of ecDNA-targeted therapies. We look forward to continuing our successful partnership with Merck and our joint journey towards a deeper understanding of complex life-threatening diseases.”
For high resolution please click the image.
About BioMed X
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. We operate at the interface between academia and industry, performing biomedical research and drug discovery & development in the fields of oncology, immunology, neuroscience, platform technologies, and artificial intelligence.
All our research projects are supported by leading pharmaceutical companies and conducted by early-career scientists recruited from the best schools around the world. The combination of global crowdsourcing with local incubation of the best research talents and ideas allows us to solve the biggest challenges in biomedical research.
We stand for free, creative, and curiosity-driven research combined with a solid validation of results, timelines, and deliverables. We serve a large purpose in advancing translational biomedicine by leveraging synergies and fostering cross-pollination across disciplines.
Contact
BioMed X
Maria Morganti
Head of Marketing
+49 155 66963726
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: International Cooperation; Academies and Institutes; Drug Discovery; Biomedical Research; Academies and Institutes; Early Detection of Cancer; Genetic Techniques; Germany; BioMed X Institute; Merck; Extrachromosomal DNA (ecDNA); Cancer research; Oncology; Precision oncology; Single-cell screening; Spatial technologies; Dr. Alexandros Drainas; Dr. Sebastian M. Waszak; Dr. Balca Mardin; Target Discovery & Research; Cancer cell adaptability; Cancer heterogeneity; Therapeutic resistance; ecDNA-targeted therapies; Drug discovery & development; Translational biomedicine;
Source: Biotech Newswire